If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Kisunla ™ (donanemab-azbt) injection, for intravenous infusion
350 mg/20 mL (17.5 mg/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Who is the intended patient for Kisunla™ (donanemab-azbt) treatment?
Treatment with Kisunla (donanemab) should be initiated in patients with mild cognitive impairment or mild dementia due to AD with presence of amyloid beta pathology.
See important safety information, including boxed warning, in the attached prescribing information.
Patient Identification in the Donanemab Studies
Donanemab is indicated for the treatment of Alzheimer's disease (AD). Treatment with donanemab should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease.1
Confirm the presence of amyloid beta pathology prior to initiating treatment.1
Information on patient selection in the TRAILBLAZER-ALZ 2 study is summarized.
Evidence of AD Neuropathology
Enclosed Prescribing Information
References
The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).
1Kisunla [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
2Sims JR, Zimmer JA, Evans CD, et al; TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527. https://doi.org/10.1001/jama.2023.13239
Date of Last Review: June 08, 2023